FierceMarkets

FierceMarkets
Share

FierceMarkets

 •  September 19

Catalent signaled a year ago that it was looking for the right M&A target to bulk up like some of its competitors have. Now it says it has found one, having agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana. Somerset, New Jersey-based Catalent announced it will pay $750...

FierceMarkets

 •  September 18

Fosun seems determined to take control of India’s Gland Pharma. After its $1.26 billion deal for an 86% stake was reportedly struck down by India’s cabinet, the Chinese pharma has dialed down the offer to $1.1 billion for 74%. And that's just enough to circumvent the Indian government’s scrutiny. However, Fosun didn’t cite the regulatory blockade...

FierceMarkets

 •  September 7

Mylan last spring recalled tens of thousands EpiPen injectors that had been manufactured by a Pfizer unit that were potentially faulty. It turns out the recalls came right after an FDA inspection at the Meridian Medical Technologies plant, where the FDA found it had been producing the pens even in the face of mounting evidence many were failing...

FierceMarkets

 •  September 5

Even as the drug industry faces a host of growth-stunting challenges, a new report highlights some positive news from an employment point of view. U.S. pharma firms terminated fewer employees this year than at the same point in 2016, according to the analysis. Outplacement consultancy Challenger, Gray & Christmas tallied U.S. drug companies’...

FierceMarkets

 •  August 16

One day after committing to remain on President Donald Trump's manufacturing council, Johnson & Johnson CEO Alex Gorsky on Wednesday decided to bow out in the wake of new remarks from the president. The decision came about the same time Trump ended the panel, as the president announced via Twitter. Both decisions follow Merck CEO Ken Frazier’s move...

FierceMarkets

 •  August 15

ACHIEVE COST-EFFICIENCIES AND SPEED DATA DELIVERY: The Benefits of Combining Bioanalytical and Central Laboratory Services for Clinical Trials As sponsors require higher throughput, managers are forced to do more with the same or fewer resources, which causes a strain in scientific depth. This pressure increases as the complexities of therapeutic...

FierceMarkets

 •  August 15

The word “deal” has a curiously apt set of meanings when it comes to M&A. It’s the hook-up of two companies, of course. But according to the Oxford English Dictionary, it also means “to cope with or control” and “take measures ... especially with the intention of putting something right.” Pharma deals are certainly designed to do both: cope with...

FierceMarkets

 •  August 10

Perrigo surprised its investors Thursday when it turned in much better than expected results for the second quarter, but it still reported a loss and continues to slim down and firm up as it works off debt. Part of that ongoing fiscal fitness program was its announced sale Thursday of its active pharmaceutical business for $110 million. Perrigo...

FierceMarkets

 •  August 10

The biggest Big Pharmas back in 2007 are still the biggest today. Johnson & Johnson has $72 billion in revenue now, $61 billion back then; Pfizer, $53 billion, up from $48 billion; Roche, $50 billion, up from $38 billion; Novartis, $49 billion, up from $38 billion. But among the top 15 pharma companies ranked by 2016 revenue, several weren’t even...

FierceMarkets

 •  August 10

With the failed attempt to repeal and replace Obamacare in the rearview mirror, President Donald Trump and members of Congress are moving on to other issues, including tax reform. Just exactly what changes to the tax code might look like has yet to become clear, but one thing can be said for certain: Trump wants to lower the tax burden for...